Prolaris cell cycle progression test for localized prostate cancer: OHTAC Recommendation
Ontario Health Technology Advisory Committee (OHTAC)
Record ID 32017000348
English
Authors' recommendations:
After considering the available evidence on clinical utility, budget impact, and lived experience,
as well as patient preferences and values, the committee reached consensus that there is
uncertainty about the potential clinical benefits of this test. The clinical evidence is limited, there
is uncertainty about its generalizability, and there remains an important gap in information on
how adding this test to clinical practice in Ontario would affect patient-important outcomes, such
as quality of life or mortality. In addition, the test is expensive, both on an individual basis and in
terms of the total budget impact.
Details
Project Status:
Completed
Year Published:
2017
URL for published report:
http://www.hqontario.ca/Portals/0/documents/evidence/reports/recommendation-prolaris-1705-en.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Cell Division
- Humans
- Male
- Prostatic Neoplasms
Contact
Organisation Name:
Health Quality Ontario
Contact Address:
Evidence Development and Standards, Health Quality Ontario, 130 Bloor Street West, 10th floor, Toronto, Ontario Canada M5S 1N5
Contact Name:
EDSinfo@hqontario.ca
Contact Email:
OH-HQO_hta-reg@ontariohealth.ca
Copyright:
Health Quality Ontario (HQO)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.